FDA panel advises taking preterm birth drug off the market

An FDA advisory panel voted 14-1 on Wednesday to recommend that the agency withdraw its approval of the drug Makena, saying the treatment does not appear to reduce the risk of preterm birth.

That proposal was challenged by drug maker Covis Pharma, which is based in Luxembourg and has U.S. offices in King of Prussia. The, given that there were few effective treatments for preventing premature birth. In a recent report, an oversight office at the U.S. Department of Health and Human Services found flaws with the accelerated process through which Makena and certain other drugs are approved.

Among the panel members who voted no in Wednesday’s hearing was biostatistician Susan S. Ellenberg, a professor emerita at the University of Pennsylvania’s Perelman School of Medicine.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA Advisers Recommend Pulling Drug to Prevent Preterm Births From MarketThe obstetricians and other reproductive-health experts voted after various studies found the drug didn’t provide a benefit but did increase the risk of blood clots and other side effects. So why is mrna injections pulled after the data was forcefully pulled from Pfizer instead of waiting 75 years?Bet there won't be an answer.
Source: WSJ - 🏆 98. / 63 Read more »

FDA Says Makena Doesn't Prevent Premature Births, Seeks to Pull Drug From MarketThe maker of the only U.S. drug intended to prevent premature births is making a last-ditch effort to keep its medication on the market as health regulators revisit mounting evidence that it doesn't work
Source: NBCLA - 🏆 319. / 59 Read more »